Skip to search formSkip to main contentSkip to account menu

Lurbinectedin

A synthetic tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogue with potential antineoplastic activity. Lurbinectedin covalently binds… 
National Institutes of Health

Related topics

Related topics

7 relations
DNADNA CrosslinkingDNA IntercalationDNA Synthesis Inhibition

Narrower (1)

PM 01183

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors: Updated results from a phase Ib-II trial.
3514Background: LUR is a novel agent that exerts antitumor activity through inhibition of trans-activated transcription and… 
2018
2018
Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): Results from a phase 2 study.
8570Background: SCLC is a deadly cancer and despite initial 80% response, almost all patients (pts) will relapse and die of this… 
2018
2018
Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.
11519Background: Patients (pts) with relapsed Ewing sarcoma (ES) have a poor outcome. New therapeutic agents are needed. L is a… 
2018
2018
ATLANTIS: Global, randomized phase III study of lurbinectedin (L) with doxorubicin (DOX) vs. CAV or topotecan (T) in small-cell lung cancer after platinum therapy.
TPS8587Background: Lurbinectedin (L), a synthetic analog of marine-based tetrahydroisoquinolone, blocks active transcription… 
2017
2017
New treatments in ovarian cancer.
In targeting DNA repair pathways of the most genomic instable cancer, poly-(adenosine diphosphate [ADP])-ribose polymerase… 
Review
2017
Review
2017
Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer
5586Background: Lurbinectedin (L) is a new anticancer drug that blocks trans-activated transcription, induces DNA double-strand… 
2016
2016
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair
Trabectedin (Yondelis®, ecteinascidin-743, ET-743) is a marine-derived natural product approved for treatment of advanced soft… 
2016
2016
CORAIL trial: Randomized phase III study of lurbinectedin (PM01183) versus pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with platinum-resistant ovarian cancer.
TPS5597Background: PM01183 (PM; lurbinectedin) is a new anticancer drug that blocks trans-activated transcription, induces DNA… 
2016
2016
Abstract 1284: Lurbinectedin reduces tumor-associated macrophages and the production of inflammatory cytokines, chemokines, and angiogenic factors in preclinical models
Lurbinectedin, currently undergoing clinical evaluation in ovarian, breast and small-cell lung cancer patients, inhibits active… 
2015
2015
Abstract P3-13-01: Lurbinectedin (PM01183) activity in BRCA1/2-associated or unselected metastatic breast cancer. Interim results of an ongoing phase II trial
Background: Metastatic breast cancer (MBC) is a clinically heterogeneous disease in which selective approaches are needed to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)